<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01901861</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005660-98</org_study_id>
    <nct_id>NCT01901861</nct_id>
  </id_info>
  <brief_title>Effect of a Single Oral Dose DPP-4 Inhibitor Sitagliptin on Islet Function After Intake of a Standardized Mixed Meal in Patients With Type 2 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      study hypothesis to examine the acute effects on glycaemia and islet hormone secretion of
      increased levels of endogenous GLP-1 and GIP on islet cell function in men with type 2
      diabetes. To this purpose, a standardized mixed meal test will be ingested with or without
      concomitant administration of sitagliptin (100mg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In men subjects with type 2 diabetes treated with diet and exercise with or without
      metformin treatment as an antidiabetic agent, a standardized mixed meal test will be served
      with or without administration of sitagliptin (100mg).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Release of incretins hormones</measure>
    <time_frame>300 min</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>type 2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The standard mixed meal test will be served 30min after intake of sitagliptin 100mg .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 2 diabetes without sitagliptin 100mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A standard mixed meal test will be served without sitagliptin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <arm_group_label>type 2 diabetes</arm_group_label>
    <arm_group_label>type 2 diabetes without sitagliptin 100mg</arm_group_label>
    <other_name>Mixed meal test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian men with type 2 diabetes diagnosed according to ICD10

          -  Ongoing treatment with life style adjustment or life style adjustment together with
             metformin as oral antidiabetic. Metformin therapy should not exceed 2 grams daily

          -  Age 20-75 years

          -  HbA1c â‰¤80 mmol/mol

          -  BMI: 20-40 kg/m2

        Exclusion Criteria:

          -  Liver disease or ALAT three times above upper reference range

          -  Diabetic nephropathy (GFR &lt; 50 mL/min/1.73 m2 or albuminuria)

          -  Proliferative diabetic retinopathy

          -  Treatment with any glucose-lowering medication except metformin

          -  Previous myocardial infarction, coronary heart disease or insatiable angina pectoris
             in the last 6 months.

          -  Previous surgery on the gastrointestinal tract

          -  Larger surgical intervention during the last 12 weeks

          -  Treatment with oral steroids or thiazide diuretics

          -  Treatment with digoxin

          -  Smokers

          -  Participation in another study the last 4 weeks

          -  Paracetamol intolerance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahren, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Science Lund,Lund University</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 14, 2013</lastchanged_date>
  <firstreceived_date>July 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>glucagon-like peptide-1 (GLP-1),glucose-dependent insulinotropic polypeptide(GIP), dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
